DCLRE1B

Across TCGA pan-cancer cohorts, DCLRE1B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCLRE1B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher DCLRE1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCLRE1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, PRAD, and SARC are the cancer types where DCLRE1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
PRAD	DFS	Median	All	0.076	0.774	<.001	6	view →
SARC	OS	Median	All	0.174	0.730	.006	3	view →
GBM	OS	Median	All	0.070	0.416	.003	3	view →
UCEC	DFS	Median	All	0.952	0.621	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DCLRE1B–SCLC (DFS)

Open the SCLC breakdown →